Aspirin in the secondary prevention of cardiovascular disease: An update of the APTC meta-analysis

Fundamental and Clinical Pharmacology

Volumn 24, Issue 3, 2010, Pages 385-391

  Lièvre, Michel ^a   Cucherat, Michel ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Aspirin; Cardiovascular disease; Meta analysis; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ARTERY DISEASE; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

ASPIRIN; CARDIOVASCULAR DISEASES; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SECONDARY PREVENTION;

EID: 77952575906     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00769.x     Document Type: Article

References (25)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 324 71 86.
2. Lechat P., Priollet P. Prévention des événements ischémiques majeurs au cours de l'artériopathie oblitérante des membres inférieurs: l'aspirine a-t-elle un role? J. Des maladies vasculaires (2006) 31 129 134.
3. CAPRIE steering committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348 1329 1339.
4. Sobel M., Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease. American college of chest physicians evidence-based clinical practice guidelines, 8th edn. Chest (2008) 133 815S 843S. (Pubitemid 351892977)
5. http://www.bmj.com/cgi/content/full/324/7329/71/DC1/3 (accessed on June 9, 2008).
6. http://www.spc.univ-lyon1.fr/easyma.net/.
7. Bradburn M.J., Deek J.J., Berlin J.A., Localio A.R. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statist. Med. (2007) 26 53 77.
8. Higgins J.P.T., Thompson S.G. Quantifying heterogeneity in a metaanalysis. Stat. Med. (2002) 21 1539 1558.
9. Horrocks M., Horrocks E.H., Murphy P., et al. The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty. Int. Angiol. (1997) 16 101 106. (Pubitemid 27353141)
10. Lee T.K., Chan K.W., Huang Z.S., et al. Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan. Thromb. Res. (1997) 87 215 224.
11. Rödén-Jüllig Å., Britton M., Malmkvist K., Leijd B. Aspirin in the prevention of progressing stroke: a randomized controlled study. J. Intern. Med. (2003) 254 584 590. (Pubitemid 37521855)
12. Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J. Intern. Med. (2007) 261 276 284. (Pubitemid 46255949)
13. Harjola P.T., Meurala H., Frick M.H. Prevention of early reocclusion by dipyridamole and ASA in arterial reconstructive surgery. J. Cardiovasc. Surg. (Torino) (1981) 22 141 144. (Pubitemid 11093776)
14. Brown B.G., Cukignan R.A., DeRouen T., et al. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation (1985) 72 138 146.
15. Sanz G., Pajaron A., Alegria E., et al., the Grupo Espanol para el Seguimiento del Injerto Coronario (GESIC). Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation (1990) 82 765 773. (Pubitemid 20316727)
16. Savage M.P., Goldberg S., Bove A.A., et al., The M-HEART II study group. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. multi-hospital eastern atlantic restenosis trial (M-HEART II). Circulation (1995) 92 3194 3200.
17. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European stroke prevention study 2. Dipyridamole and acetylsalicyclic acid in the secondary prevention of stroke. J. Neurol. Sci. (1996) 143 1 13. (Pubitemid 26402780)
18. ESPS 2 Group. European stroke prevention study: 2. Efficacy and safety data. J. Neurol. Sci. (1997) 151 S1 S77.
19. Hess H., Mietaschk A., Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet (1985) 1 415 419.
20. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet (2006) 367 1665 1673.
21. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy. BMJ (1994) 308 81 106.
22. Peters R.J.G., Mehta S.R., Fox K.A.A., et al. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation (2003) 108 1682 1687.
23. Patrono C., García Rodríguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. (2005) 353 2373 2383. (Pubitemid 41713749)
24. Boissel J.P. Place des antiagrégants dans le traitement des artériopathies des membres inférieurs. Arch. Mal. Coeur (1991) 84 1721 1724.
25. Cacoub P.P., Bhatt D.L., Steg P.G., Topol E.J., Creager M.A., for the CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur. Heart J. (2009) 30 192 201.